share_log

Conduit Pharmaceuticals | NT 10-K: Others

Conduit Pharmaceuticals | NT 10-K: Others

Conduit Pharmaceuticals | NT 10-K:其他
美股SEC公告 ·  04/01 16:58

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals Inc., previously known as Murphy Canyon Acquisition Corp., has filed a notification of late filing with the SEC for its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company, headquartered at 4995 Murphy Canyon Road, Suite 300, San Diego, CA, cited the inability to compile the necessary financial statements and related disclosures without unreasonable effort or expense as the reason for the delay. Conduit Pharmaceuticals anticipates filing the report by the extended deadline, which is the fifteenth calendar day following the original due date. The company also indicated that there would be a significant change in the results of operations compared to the previous fiscal year due to the business combination and commencement of operations as an operating company since September 2023. The notification was signed by David Tapolczay, Chief Executive Officer, on April 1, 2024.
Conduit Pharmaceuticals Inc., previously known as Murphy Canyon Acquisition Corp., has filed a notification of late filing with the SEC for its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company, headquartered at 4995 Murphy Canyon Road, Suite 300, San Diego, CA, cited the inability to compile the necessary financial statements and related disclosures without unreasonable effort or expense as the reason for the delay. Conduit Pharmaceuticals anticipates filing the report by the extended deadline, which is the fifteenth calendar day following the original due date. The company also indicated that there would be a significant change in the results of operations compared to the previous fiscal year due to the business combination and commencement of operations as an operating company since September 2023. The notification was signed by David Tapolczay, Chief Executive Officer, on April 1, 2024.
Conduit Pharmicals Inc.(前身爲墨菲峽谷收購公司)已向美國證券交易委員會提交了延遲提交截至2023年12月31日財年的10-K表年度報告的通知。該公司總部位於加利福尼亞州聖地亞哥墨菲峽谷路4995號300套房,該公司指出,如果沒有不合理的努力或費用,就無法編制必要的財務報表和相關披露是延遲的原因。Conduit Pharmicals預計將在延長的截止日期,即原定到期日之後的第十五個日曆日之前提交報告。該公司還表示,由於業務合併以及自2023年9月以來作爲運營公司開始運營,經營業績與上一財年相比將發生重大變化。該通知由首席執行官大衛·塔波爾扎伊於2024年4月1日簽署。
Conduit Pharmicals Inc.(前身爲墨菲峽谷收購公司)已向美國證券交易委員會提交了延遲提交截至2023年12月31日財年的10-K表年度報告的通知。該公司總部位於加利福尼亞州聖地亞哥墨菲峽谷路4995號300套房,該公司指出,如果沒有不合理的努力或費用,就無法編制必要的財務報表和相關披露是延遲的原因。Conduit Pharmicals預計將在延長的截止日期,即原定到期日之後的第十五個日曆日之前提交報告。該公司還表示,由於業務合併以及自2023年9月以來作爲運營公司開始運營,經營業績與上一財年相比將發生重大變化。該通知由首席執行官大衛·塔波爾扎伊於2024年4月1日簽署。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息